Skip to main content

Table 7 Odds Ratios for Discontinuation Due to Lack of Efficacy

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

PLO 0.65 [0.19, 1.60] 0.50 [0.20, 1.04] 0.42 [0.14, 0.93] 0.23 [0.12, 0.40] 1.84 [0.54, 4.88] 0.77 [0.18, 2.17]
  ARI 1.02 [0.21, 3.06] 0.86 [0.16, 2.68] 0.47 [0.11, 1.30] 3.79 [0.62, 13.01] 1.58 [0.21, 5.73]
   CAR 1.01 [0.23, 2.83] 0.54 [0.17, 1.33] 4.41 [0.89, 14.22] 1.84 [0.31, 6.17]
    OLA 0.68 [0.19, 1.84] 5.55 [1.03, 19.22] 2.32 [0.35, 8.31]
     QUE 8.91 [2.12, 26.64] 3.72 [0.71, 11.61]
      ZIP 0.57 [0.07, 2.06]
       LUR
  1. Note: All-Cause Discontinuation results are on the top-right and Discontinuation Due to Adverse Events results are on the bottom-left. Numbers represent the odds ratio [95% credible interval]. In the top-right comparisons, the row treatment is the reference treatment. In the bottom-left, the column treatment is the reference category
  2. Abbreviations: PLO Placebo, ARI Aripiprazole, CAR Cariprazine, LUR Lurasidone, OLA Olanzapine, QUE Quetiapine, ZIP Ziprasidone